cough variant asthma
Conditions
Interventions
Experimental group :chinese medicine+ Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation
Control group :chinese medicine placebo+ Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients meet the criteria of cough variant asthma; 2. Patients had been diagnosed with CVA for the first time; 3. aged 18-65 years; 4. Patients agreed to accept corresponding treatment and follow-up and sign the informed consent file.
Exclusion criteria
Exclusion criteria: 1. Patients had accepted systematic treatment of anti-inflammatory drug or traditional Chinese medicine; 2. Patients with severe primary disease of circulatory system, respiratory System, digestive system, urinary system, endocrine system and hematopoietic system,and conventional drugs can't control the illness; Patients with cancers; Patients with severe infection or water, electrolyte and acid-base balance disorders; 3. Patients who are pregnant, have a pregnancy plan or those who are nursing; 4. Patients who are allergy to the medicines of our study; 5. Patients who are participating or have participated clinical trials in the last one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cough symptom scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| FEV1;EOS;ECP;IL-5, IL-10, IL-17;IgE;CD4, CD8; | — |
Countries
China
Contacts
Public ContactZhang Zhongde
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed